R
Robert Dreicer
Researcher at University of Virginia
Publications - 104
Citations - 9890
Robert Dreicer is an academic researcher from University of Virginia. The author has contributed to research in topics: Prostate cancer & Docetaxel. The author has an hindex of 20, co-authored 104 publications receiving 7339 citations. Previous affiliations of Robert Dreicer include National Foundation for Cancer Research.
Papers
More filters
Journal ArticleDOI
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg,Jean H. Hoffman-Censits,Thomas Powles,Michiel S. van der Heijden,Arjun Vasant Balar,Andrea Necchi,Nancy A. Dawson,Peter H. O'Donnell,Ani Balmanoukian,Yohann Loriot,Sandy Srinivas,Margitta Retz,Petros Grivas,Richard W. Joseph,Matthew D. Galsky,Mark D. Fleming,Daniel P. Petrylak,Jose Luis Perez-Gracia,Howard A. Burris,Daniel Castellano,Christina Canil,Joaquim Bellmunt,Dean F. Bajorin,Dorothee Nickles,Richard Bourgon,Garrett M. Frampton,Na Cui,Sanjeev Mariathasan,Oyewale O. Abidoye,Gregg Fine,Robert Dreicer +30 more
TL;DR: Treatment with atezolizumab resulted in a significantly improved RECIST v1.1 response rate, compared with a historical control overall response rate of 10%, and Exploratory analyses showed The Cancer Genome Atlas (TCGA) subtypes and mutation load to be independently predictive for response to atezolediazepine.
Journal ArticleDOI
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher Sweeney,Yu-Hui Chen,Michael A. Carducci,Glenn Liu,David F. Jarrard,Mario A. Eisenberger,Yu-Ning Wong,Noah M. Hahn,Manish Kohli,Matthew M. Cooney,Robert Dreicer,Nicholas J. Vogelzang,Joel Picus,Daniel H. Shevrin,Maha Hussain,Jorge A. Garcia,Robert S. DiPaola +16 more
TL;DR: Six cycles of docetaxel at the beginning of ADT for metastatic prostate cancer resulted in significantly longer overall survival than that with ADT alone.
Journal ArticleDOI
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Arjun Vasant Balar,Matthew D. Galsky,Jonathan E. Rosenberg,Thomas Powles,Daniel P. Petrylak,Joaquim Bellmunt,Yohann Loriot,Andrea Necchi,Jean H. Hoffman-Censits,Jose Luis Perez-Gracia,Nancy A. Dawson,Michiel S. van der Heijden,Robert Dreicer,Sandy Srinivas,Margitta Retz,Richard W. Joseph,Alexandra Drakaki,Ulka N. Vaishampayan,Srikala S. Sridhar,David I. Quinn,Ignacio Duran,David R. Shaffer,Bernhard J. Eigl,Petros Grivas,Evan Y. Yu,S. Li,Edward E. Kadel,Zachary Boyd,Richard Bourgon,Priti S. Hegde,Sanjeev Mariathasan,Ann Christine Thastrom,Oyewale O. Abidoye,Gregg Fine,Dean F. Bajorin +34 more
TL;DR: Atezolizumab showed encouraging durable response rates, survival, and tolerability, supporting its therapeutic use in untreated metastatic urothelial cancer.
Journal ArticleDOI
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher,Michael J. Morris,Walter M. Stadler,Celestia S. Higano,Ethan Basch,Karim Fizazi,Emmanuel S. Antonarakis,Tomasz M. Beer,Michael A. Carducci,Kim N. Chi,Paul G. Corn,Johann S. de Bono,Robert Dreicer,Daniel J. George,Elisabeth I. Heath,Maha Hussain,Wm. Kevin Kelly,Glenn Liu,Christopher J. Logothetis,David M. Nanus,Mark N. Stein,Dana E. Rathkopf,Susan F. Slovin,Charles J. Ryan,Oliver Sartor,Eric J. Small,Matthew R. Smith,Cora N. Sternberg,Mary-Ellen Taplin,George Wilding,Peter S. Nelson,Lawrence H. Schwartz,Susan Halabi,Philip W. Kantoff,Andrew J. Armstrong +34 more
TL;DR: The concept of no longer clinically benefiting is introduced to underscore the distinction between first evidence of progression and the clinical need to terminate or change treatment, and the importance of documenting progression in existing lesions as distinct from the development of new lesions.
Journal ArticleDOI
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
Christos Kyriakopoulos,Yu-Hui Chen,Michael A. Carducci,Glenn Liu,David F. Jarrard,Noah M. Hahn,Daniel H. Shevrin,Robert Dreicer,Maha Hussain,Mario A. Eisenberger,Manish Kohli,Elizabeth R. Plimack,Nicholas J. Vogelzang,Joel Picus,Matthew M. Cooney,Jorge A. Garcia,Robert S. DiPaola,Christopher Sweeney +17 more
TL;DR: The clinical benefit from chemohormonal therapy in prolonging OS was confirmed for patients with high-volume disease; however, for patientsWith low- volume disease, no OS benefit was discerned.